Brunel is a privately owned pharmaceutical business with a primary footprint in South Africa. Brunel has been servicing the pharmaceutical market for over forty years. Brunel’s business segments span across proprietary products which include pharmaceuticals and complementary medicines, dispensary consumables and certain distribution agreements.Brunel was established in 1974 by Mr Dawie de Bruin and Mr Louis Nel. The company was based in Centurion, South Africa and was originally launched doing third party sales predominantly for Beige Pharmaceuticals and the sale of its first product, a specialised hand and body lotion called Lotio Brunel, which is still on the market today.
In 1978 Brunel acquired the Famucaps Brand. In 1979 Brunel acquired a further range of pharmaceutical products. In 1986 Brunel moved into the building at 1 Van Tonder Street, Sunderland Ridge, Pretoria and obtained all necessary regulatory licenses.
In 2010 Calibre Capital acquired Brunel. Following the acquisition of Brunel many changes were made which included management, the launch of new products, key acquisitions and solid organic growth.
Brunel’s distribution facility is a custom-built, fully temperature and access controlled, 1,800 square metre facility situated in Centurion, South Africa. Fully licensed by the South African Health Products Regulatory Authority, the facility provides an end-to-end service, which includes all necessary regulatory capabilities.
Brunel has the ability to deliver from the manufacturer to the customer’s door without being reliant on third party and wholesale distribution channels. Brunel has over 2,200 active customer accounts with approximately 1,700 being managed on a month-to-month basis.
